Management Team

Kiadis Pharma has a seasoned senior leadership team consisting of highly experienced industry professionals with complementary skill sets. The team has an established track record in pursuing drug discovery and development as well as deal-making objectives, both in smaller biotechnology companies and in large pharmaceutical companies.

Arthur Lahr

Chief Executive Officer

Arthur Lahr joined Kiadis Pharma in 2017 and is Chief Executive Officer. Mr. Lahr brings more than 20 years of experience within the healthcare sector to Kiadis Pharma. Before joining Kiadis Pharma, he was chief strategy officer and a member of the management committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011. Prior to Crucell, he was a consultant at McKinsey & Company and an engineer at Unilever. At present, Mr. Lahr also serves as a member of the supervisory board of Sanquin, the Dutch national plasma and blood product supplier. Mr. Lahr holds a Master’s degree in Applied Physics from the University of Delft, The Netherlands, and a MBA from INSEAD, France.

Dirk De Naeyer

Chief Operations Officer

Dirk De Naeyer joined Kiadis Pharma in 2018 and is Chief Operations Officer. Mr. De Naeyer brings nearly 20 years of experience leading operations in both clinical and commercial-stage biotechnology companies. Prior to joining Kiadis Pharma, he was at Janssen Pharmaceuticals where he spent 14 years in various leadership positions. Most recently, Mr. De Naeyer was co-lead for the integration of Actelion into Janssen. Prior to that, he was the head of the Janssen Global Clinical Operations team and held multiple supply chain and operations leadership positions. This included heading up the Janssen Clinical Supply Chain, overseeing all active pharmaceutical ingredient (API) and Drug Product manufacturing, Packaging and Distribution for Janssen R&D, which covered Small Molecules, Biologics and Stem Cell therapies. Mr. De Naeyer joined Janssen after five years at McKinsey & Company. He holds a degree in Engineering from the KU Leuven, Belgium, and a MBA from the University of Chicago. Mr. De Naeyer is a Belgian citizen.

Amy Sullivan

Chief Strategy Officer

Amy Sullivan joined Kiadis in January 2019 as senior vice president, corporate affairs and in December 2019 was promoted to Chief Strategy Officer responsible for fundraising, investor relations, public affairs and corporate communications. Ms. Sullivan has more than 25 years of experience raising capital and building and managing corporate biotechnology and life sciences brands. She joins Kiadis Pharma from Keryx Biopharmaceuticals where she was senior vice president of corporate affairs, responsible for all aspects of investor relations, corporate communication, and public affairs, during a period of high growth, commercialization of the company’s first FDA-approved medicine and, ultimately, a merger. Prior to Keryx, Ms. Sullivan served as head of corporate communications and investor relations at AMAG Pharmaceuticals, Idenix Biopharmacueticals and Genencor International. Ms. Sullivan has a Bachelor of Science degree in business from Salem State University and a MBA from Bentley University.

Robert Friesen

Chief Scientific Officer

Robert Friesen, PhD, joined Kiadis Pharma in 2019 and is Chief Scientific Officer. Dr. Friesen has more than 20 years of experience in the biopharmaceutical industry leading multiple Research and Development organizations. Dr. Friesen joined Kiadis Pharma from Ablynx where he was CSO until its acquisition by Sanofi. Prior to Sanofi, he served as senior vice president of ProQR Therapeutics, a clinical stage biotechnology company, heading the science and early development division. Prior to joining ProQR Therapeutics, Dr. Friesen worked at Janssen BioTherapeutics, a Johnson & Johnson Company, as global head of biologics research, and at the Crucell Vaccine Institute, a Johnson & Johnson Company, as vice president preclinical and clinical research. Before Crucell Vaccine Institute, he was head of preclinical & early clinical development at MorphoSys.

Martine Nolan

Senior Vice President, Quality

Martine Nolan joined Kiadis Pharma in 2019 and is Senior Vice President, Quality. Ms. Nolan brings over 20 years of experience in commercial quality and manufacturing in the pharmaceutical sector. She joined Kiadis Pharma from Amgen where she served as regional head of quality operations at the Dublin, Ireland and Breda, Netherlands sites. Prior to that Ms. Nolan served as executive director for international quality, Turkey, Middle East & Africa. Before joining Amgen, Ms. Nolan held several positions of increasing responsibility in quality operations at Schering-Plough (Merck) in Ireland, Singapore and US. Ms. Nolan holds a MSc in Cellular Physiology from University College Cork and a BSc in Biochemistry from University College Dublin.

Jonathan Sweeting

Senior Vice President, Commercial Europe

Jonathan Sweeting joined Kiadis Pharma in 2018 and is Senior Vice President, Commercial Europe. Mr. Sweeting has nearly 20 years of commercial experience. Prior to joining Kiadis Pharma, he spent over five years at GlaxoSmithKline in various leadership positions, most recently as senior vice president and head of the global respiratory franchise and previously in roles as general manager Poland and global commercialization leader for respiratory biologics. Mr. Sweeting joined GSK from AstraZeneca where he spent over eight years in global and local roles in the UK and Russia. Prior to that he was at Accenture for five years. Mr. Sweeting holds an MA (Hons) degree in Chemistry from the University of Cambridge and a MBA from INSEAD. Mr. Sweeting is a British citizen.

Scott A. Holmes

Chief Financial Officer

Scott Holmes joined Kiadis in 2019 as Chief Financial Officer and will be stepping down to pursue other opportunities effective 31 December 2019. Mr. Holmes earned a MS/MBA degree from Northeastern University and a BA in History from Middlebury College.

Andrew Sandler

Chief Medical Officer

Andrew Sandler joined Kiadis Pharma in 2017 and is Chief Medical Officer. Dr. Sandler has over 20 years of experience within the healthcare industry dedicated to hematologic malignancies and solid tumors. Prior to joining Kiadis Pharma, he was senior vice president, medical affairs, at Medivation (now part of Pfizer). Prior to that he was CMO at Dendreon Pharmaceuticals and Spectrum Pharma. He has also held senior-level positions with several leading biotechnology and pharmaceutical companies, including Bayer Healthcare, Berlex and Seattle Genetics. Dr. Sandler obtained his MD from Mount Sinai School of Medicine, New York and completed a fellowship in medical oncology at University of California San Francisco. A US citizen, Dr. Sandler is a board certified medical oncologist and has treated many patients with hematologic malignancies, including bone marrow transplant patients.

Marcel Zwaal

Senior Vice President, Corporate Development

Marcel Zwaal joined Kiadis Pharma in 2018 and is Senior Vice President, Corporate Development. Mr. Zwaal has over 20 years of experience in finance and business. Prior to joining Kiadis Pharma, he was chief executive officer of Hubrecht Organoid Technologies. Previously, Mr. Zwaal worked in corporate development at Galapagos, served as CEO of cell therapy biotech startup DCPrime and held several senior management positions at Crucell in finance and business development prior to its acquisition by Johnson & Johnson in 2011. Mr. Zwaal holds an Executive Master of Finance and Control degree and a Finance BA Master’s degree from Vrije Universiteit Amsterdam. Mr. Zwaal is a Dutch citizen.

James Joy

General Counsel and Company Secretary

James Joy joined Kiadis Pharma in 2018 and is General Counsel and Company Secretary. Mr. Joy has over 20 years of legal and corporate finance experience in a variety of industries. Prior to joining Kiadis Pharma, Mr. Joy served as general counsel at C-Map AS, TomTom NV and Navigator Asset Management and vice president Legal at Royal Ahold NV. Previously, Mr. Joy practiced law in New York and London with Latham & Watkins and Norton Rose Fulbright where he advised technology, media and industrial clients on corporate finance mergers and acquisitions. Mr. Joy holds a Bachelor’s degree in Economics from Heriot-Watt University and a Juris Doctor degree from Tulane Law School. Mr. Joy is a member of the New York State Bar.

Mark Schaefer

Chief Human Resources Officer

Mark Schaefer joined Kiadis Pharma in 2018 and is Chief Human Resources Officer. Mr. Schaefer has 25 years of global human resources experience building manufacturing and commercial operations. Prior to joining Kiadis Pharma, he was senior vice president of global human resources at Aenova Holding, a global leader in the pharmaceutical and healthcare industries and one of the leading contract manufacturers in Europe. Prior to that Mr. Schaefer worked in senior global human resources roles at West Pharmaceuticals, 3M, Sony and GE. He holds a Honors BA in Economics and Commerce as well as a Master’s degree in Industrial Relations from the University of Toronto. Mr. Schaefer is a Canadian citizen.

Paul van Hagen

Senior Vice President Finance

Paul van Hagen joined Kiadis in 2018 as vice president, finance and in December 2019 was promoted to Senior Vice President Finance and is responsible for the finance function. Mr. Van Hagen brings over 20 years of financial management expertise to Kiadis. Prior to joining Kiadis, Mr. van Hagen provided financial advice to various companies in the life science industry and served as chief financial officer of Xeltis, a medical device company. Prior to Xeltis, he held senior financial management positions at Prosensa and Crucell, both publicly listed Companies. Mr. van Hagen worked as a Senior Manager with Ernst & Young and was responsible for various international audit engagements. Mr. van Hagen is a certified public accountant and holds a Master’s degree in Business Economics from the University of Groningen in The Netherlands. Mr. van Hagen is a Dutch citizen.

Arthur Lahr

Chief Executive Officer

Dirk De Naeyer

Chief Operations Officer

Amy Sullivan

Chief Strategy Officer

Robert Friesen

Chief Scientific Officer

Martine Nolan

Senior Vice President, Quality

Jonathan Sweeting

Senior Vice President, Commercial Europe

Scott A. Holmes

Chief Financial Officer

Andrew Sandler

Chief Medical Officer

Marcel Zwaal

Senior Vice President, Corporate Development

James Joy

General Counsel and Company Secretary

Mark Schaefer

Chief Human Resources Officer

Paul van Hagen

Senior Vice President Finance